Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Turkova A, Waalewijn H, Chan MK, Bollen PDJ, Bwakura-Dangarembizi MF, Kekitiinwa AR, Cotton MF, Lugemwa A, Variava E, Ahimbisibwe GM, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo CM, Archary M, Ferrand RA, Violari A, Gibb DM, Burger DM, Ford D, Colbers A; ODYSSEY Trial Team. Turkova A, et al. Among authors: srirompotong u. Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19. Lancet HIV. 2022. PMID: 35868341 Free PMC article. Clinical Trial.
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
Sripan P, Le Coeur S, Ingsrisawang L, Cressey TR, Bouazza N, Foissac F, Ngo-Giang-Huong N, Traisathit P, Srirompotong U, Ayudhaya OP, Puangsombat A, Jungpipun J, Jittayanun K, Tréluyer JM, Jourdain G, Lallemant M, Urien S. Sripan P, et al. Among authors: srirompotong u. Antivir Ther. 2016;21(5):435-40. doi: 10.3851/IMP3001. Epub 2015 Oct 22. Antivir Ther. 2016. PMID: 26492107 Free PMC article. Clinical Trial.
Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis.
Anugulruengkitt S, Cressey TR, Suntarattiwong P, Ounchanum P, Srirompotong U, Jantarabenjakul W, Sophonphan J, Tawon Y, Punnahitanon S, Pancharoen C, Chokephaibulkit K, Puthanakit T; CIPHER_AEPEP Study Team. Anugulruengkitt S, et al. Among authors: srirompotong u. Pediatr Infect Dis J. 2019 Feb;38(2):152-156. doi: 10.1097/INF.0000000000002195. Pediatr Infect Dis J. 2019. PMID: 30204660
Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Cressey TR, Decker L, Khamduang W, Harrison L, Tierney C, Shepherd JA, Kourtis AP, Bulterys M, Siberry GK, Jourdain G. Salvadori N, et al. Among authors: srirompotong u. Clin Infect Dis. 2019 Jun 18;69(1):144-146. doi: 10.1093/cid/ciy982. Clin Infect Dis. 2019. PMID: 30924492 Free PMC article. Clinical Trial.
CHAMP+ Thailand: Pilot Randomized Control Trial of a Family-Based Psychosocial Intervention for Perinatally HIV-Infected Early Adolescents.
Nestadt DF, Saisaengjan C, McKay MM, Bunupuradah T, Pardo G, Lakhonpon S, Gopalan P, Leu CS, Petdachai W, Kosalaraksa P, Srirompotong U, Ananworanich J, Mellins CA. Nestadt DF, et al. Among authors: srirompotong u. AIDS Patient Care STDS. 2019 May;33(5):227-236. doi: 10.1089/apc.2019.0021. AIDS Patient Care STDS. 2019. PMID: 31067121 Free PMC article. Clinical Trial.
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
Anugulruengkitt S, Suntarattiwong P, Ounchanum P, Srirompotong U, Jantarabenjakul W, Sophonphan J, Punnahitanon S, Pancharoen C, Cressey TR, Chokephaibulkit K, Puthanakit T; CIPHER_AEPEP study team. Anugulruengkitt S, et al. Among authors: srirompotong u. Pediatr Infect Dis J. 2019 Oct;38(10):1045-1050. doi: 10.1097/INF.0000000000002426. Pediatr Infect Dis J. 2019. PMID: 31365477
Incidence and risk factors of loss to follow-up among HIV-infected children in an antiretroviral treatment program.
Kawilapat S, Salvadori N, Ngo-Giang-Huong N, Decker L, Kanjanavanit S, Puangsombat A, Preedisripipat K, Lertpienthum N, Akarathum N, Mekmullica J, Srirompotong U, Lallemant M, Le Coeur S, Traisathit P, Leroi C, Jourdain G. Kawilapat S, et al. Among authors: srirompotong u. PLoS One. 2019 Sep 17;14(9):e0222082. doi: 10.1371/journal.pone.0222082. eCollection 2019. PLoS One. 2019. PMID: 31527875 Free PMC article.
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY Trial Team. Moore CL, et al. BMC Infect Dis. 2021 Jan 4;21(1):5. doi: 10.1186/s12879-020-05672-6. BMC Infect Dis. 2021. PMID: 33446115 Free PMC article. Clinical Trial.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Turkova A, et al. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. N Engl J Med. 2021. PMID: 34965338 Free PMC article. Clinical Trial.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P, Lugemwa A, Wynne B, Mujuru HA, Violari A, Kityo CM, Archary M, Variava E, White E, Turner RM, Shakeshaft C, Ali S, Nathoo KJ, Atwine L, Liberty A, Bbuye D, Kaudha E, Mngqibisa R, Mosala M, Mumbiro V, Nanduudu A, Ankunda R, Maseko L, Kekitiinwa AR, Giaquinto C, Rojo P, Gibb DM, Turkova A, Ford D; ODYSSEY Trial Team. Amuge P, et al. Lancet HIV. 2022 Sep;9(9):e638-e648. doi: 10.1016/S2352-3018(22)00163-1. Lancet HIV. 2022. PMID: 36055295 Free PMC article. Clinical Trial.
17 results